MARKET

NBRV

NBRV

Nabriva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.380
+0.040
+2.99%
After Hours: 1.370 -0.01 -0.72% 17:55 06/24 EDT
OPEN
1.350
PREV CLOSE
1.340
HIGH
1.380
LOW
1.330
VOLUME
1.39M
TURNOVER
--
52 WEEK HIGH
11.50
52 WEEK LOW
1.260
MARKET CAP
68.19M
P/E (TTM)
-0.3540
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21)
Benzinga · 2d ago
Hedge Funds Never Been Less Bullish On Nabriva Therapeutics plc (NBRV)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite ...
Insider Monkey · 6d ago
When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Turn A Profit?
With the business potentially at an important milestone, we thought we'd take a closer look at Nabriva Therapeutics...
Simply Wall St. · 06/11 09:16
Crestone Joins Antimicrobials Working Group
/PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings A...
PR Newswire - PRF · 06/08 15:18
BRIEF-Nabriva Therapeutics Says Elected Lisa Dalton And Mark Corrigan As Members Of Board
reuters.com · 06/03 13:41
BRIEF-Nabriva Agrees To Extension Of Principal Debt Repayments Under Existing Loan Agreement With Hercules Capital
reuters.com · 06/03 11:57
Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital
- Principal Repayments Delayed At Least Until January 1, 2022
GlobeNewswire · 06/03 11:19
Nabriva Announces Changes to its Board of Directors
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Dr. Mark Corrigan and Lisa Dalton have joined the Co...
GlobeNewswire · 06/02 22:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBRV. Analyze the recent business situations of Nabriva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBRV stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 85
Institutional Holdings: 13.51M
% Owned: 27.34%
Shares Outstanding: 49.41M
TypeInstitutionsShares
Increased
6
236.85K
New
7
470.87K
Decreased
8
814.10K
Sold Out
6
203.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.59%
Pharmaceuticals & Medical Research
+1.22%
Key Executives
Chairman - Supervisory/Independent Director
Daniel Burgess
President/Chief Operating Officer
Steven Gelone
Chief Executive Officer/Director
Theodore Schroeder
Chief Financial Officer
Daniel Dolan
General Counsel/Secretary
Robert Crotty
Other
Francesco Lavino
Director
Colin Broom
Director
Mark Corrigan
Director
Lisa Dalton
Independent Director/Supervisory Board
Carrie Bourdow
Independent Director/Supervisory Board
Charles Rowland
Independent Director/Supervisory Board
George Talbot
Independent Director/Supervisory Board
Stephen Webster
No Data
About NBRV
Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Webull offers kinds of Nabriva Therapeutics PLC - ADR stock information, including NASDAQ:NBRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBRV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBRV stock methods without spending real money on the virtual paper trading platform.